Clinical Observation of SGLT-2 Inhibitors in Delaying the Progression of Diabetic Nephropathy

Ling ZHAO; Hongling ZHONG; Xinru GAO; Mei LI; Tingting MAO; Rongyong LI; Tingyu KE

doi:10.12259/j.issn.2095-610X.S20230527

Volume 44 Issue 5

May 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(5): 60-65

Ling ZHAO, Hongling ZHONG, Xinru GAO, Mei LI, Tingting MAO, Rongyong LI, Tingyu KE. Clinical Observation of SGLT-2 Inhibitors in Delaying the Progression of Diabetic Nephropathy[J]. Journal of Kunming Medical University, 2023, 44(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20230527

Citation:

Ling ZHAO, Hongling ZHONG, Xinru GAO, Mei LI, Tingting MAO, Rongyong LI, Tingyu KE. Clinical Observation of SGLT-2 Inhibitors in Delaying the Progression of Diabetic Nephropathy[J]. Journal of Kunming Medical University, 2023, 44(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20230527

Citation:

Ling ZHAO, Hongling ZHONG, Xinru GAO, Mei LI, Tingting MAO, Rongyong LI, Tingyu KE. Clinical Observation of SGLT-2 Inhibitors in Delaying the Progression of Diabetic Nephropathy[J]. Journal of Kunming Medical University, 2023, 44(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20230527

PDF( 619 KB)

Clinical Observation of SGLT-2 Inhibitors in Delaying the Progression of Diabetic Nephropathy

doi: 10.12259/j.issn.2095-610X.S20230527

1.
Dept. of Endocrinology，The 2nd Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650101
2.
The 2nd Clinical Medical College of Kunming Medical University，Kunming Yunnan 650101，China

Received Date: 2023-02-17
Available Online: 2023-05-10
Publish Date: 2023-05-25

Abstract

Abstract

Objective To investigate the clinical efficacy of SGLT2 inhibitors in delaying the progression of diabetic nephropathy based on "real world" clinical data. Methods A retrospective analysis was performed on 98 patients with diabetes who were treated with SGLT2 inhibitors from the MMC database of the Second Affiliated Hospital of Kunming Medical University from January 2019 to December 2022. The baseline data of treatment with SGLT2 inhibitors were taken as the baseline and the data of 6 months of treatment were collected. （1） General data [age, sex, height, BMI, systolic blood pressure, diastolic blood pressure] were compared between baseline and 6 months of the treatment; （2） Indexes of glucose metabolism [blood glucose, glycosylated hemoglobin （HbA1c）]; （3） Liver function indexes [AST, ALT, alkaline phosphatase, YGT, ALB]; （4） Lipid indexes [total cholesterol （TC）, triglyceride （TG）, high density lipoprotein （HDLc）, low density lipoprotein （LDLc）]; （5） Renal function indicators [urinary creatinine, urinary microalbumin, urinary microalbumin/creatinine （UACR）, urea nitrogen （BUN）, uric acid （UA）, creatinine （Cr）]. Following the "6 month interval" method, 98 patients with relatively complete data admitted to the hospital from January 2019 to December 2022 were divided into baseline group （98 cases, initial use of SGLT2 inhibitor） and 6 month group （98 cases, SGLT2 inhibitor treatment for 6 months）. Results The baseline age of the patients included in this study was 52.85±8.98 years old, and the baseline height was 167.62±8.04cm, including 72 males, accounting for 73.47%, and 26 females, accounting for 26.53%.After the 6 months of treatment: （1） The BMI, systolic blood pressure and diastolic blood pressure of the patients were lower than the baseline. There were significant differences in diastolic blood pressure （P < 0.05）. （2） The indexes of glucose metabolism, blood glucose and HbA1c were lower than the baseline, and the differences between the two indexes were statistically significant （P < 0.05）. （3） The liver function indexes AST, ALT, ALP, YGT and ALB were lower than the baseline, and the difference in ALT was statistically significant （P < 0.05）. （4） Lipid indexes TC, TG and LDLc were lower than the baseline, while HDLc was higher than the baseline, and the difference between TG and HDLc indexes was statistically significant （P < 0.05）. （5） The renal function indexes as urinary microalbumin, urinary microalbumin/creatinine （UACR） and urea nitrogen （BUN） were lower than the baseline, urinary creatinine, uric acid （UA） and creatinine （Cr） were higher than the baseline, and the differences in urinary microalbumin/creatinine （UACR） indexes were statistically significant （P<0.05）. Adverse reactions: In this study, no hypoglycemia, severe gastrointestinal reaction, urinary tract infection, lower limb wound injury or amputation were observed between the two groups. Conclusion SGLT2 inhibitors have the effects of lowering blood pressure, reducing body massindex controlling blood sugar level, regulating lipid metabolism, improving the renal function and reducing urinary protein in diabetic nephropathy patients. It can delay the progression of diabetic nephropathy and has high clinical safety.
- Diabetic nephropathy,
- SGLT2 inhibitors,
- Clinical efficacy,
- Safety

FullText(HTML)

References(22)

References

[1]	Chinese Diabetes Society (中华医学会糖尿病学分会). China guideline for type 2 diab-etes (2013)[J]. 中国糖尿病杂志,2014,6(7):447-498.
[2]	林嘉欣,张欣洲. SGLT2抑制剂及其治疗慢性肾脏病合并糖尿病患者的研究概况[J]. 内科,2021,16(5):640-642,706. doi: 10.16121/j.cnki.cn45-1347/r.2021.05.21
[3]	Collins A J,Foley R N,Chavers B,et al. USRDS 2012 annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States[J]. Am J Kidney Dis,2012,59(S1):A7,e1-e420.
[4]	Tagawa A,Yasuda M,Kume S,et al. Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy[J]. Diabetes,2016,65(3):755. doi: 10.2337/db15-0473
[5]	Gnudi L,Coward R J M,Long D A. Diabetic nephropathy: Perspective on novel molecular mechanisms[J]. Trends Endocrinol Metab,2016,27(11):820. doi: 10.1016/j.tem.2016.07.002
[6]	Chan G C,Tang S C. Diabetic nephropathy: Landmark clinical trials and tribulations[J]. Nephrol Dial Transplant,2016,31(3):359. doi: 10.1093/ndt/gfu411
[7]	Ha M,Choi S Y,Kim M,et al. Diabetic nephropathy in type 2 diabetic retinopathy requiring panretinal photocoagulation[J]. Korean J Ophthalmol,2019,33(1):46. doi: 10.3341/kjo.2018.0034
[8]	Ma R,Ren J M,Li P,et al. Activated YAP causes renal damage of type 2 diabetic nephropathy[J]. Eur Rev Med Pharmacol Sci,2019,23(2):755.
[9]	Liao D,Ma L,Liu J,et al. Cigarette smoking as a risk factor for diabetic nephropathy: A systematic review and meta-analysis of prospective cohort studies[J]. PLoS One,2019,14(2):e0210213. doi: 10.1371/journal.pone.0210213
[10]	Schrauben S J,Jepson с,Hsu J Y,et al. Insulinresistance and chronic kidneydisease progression,cardiovascular events,and death: Findings from thechronic renal insufficiency cohort study[J]. BMC Nephrol,2019,20(1):60. doi: 10.1186/s12882-019-1220-6
[11]	林忠秋,陈俊,黄振光,等. 基于OpenFDA挖掘与评价达格列净上市后的不良反应[J]. 中国医院药学杂志,2021,41(20):2095-2098,2120. doi: 10.13286/j.1001-5213.2021.20.10
[12]	Nadkarni G N,Ferrandino R,Changa,et al. Acute kidney injury in patients on SGLT2 inhibitors:A propensity-matched analysis[J]. Diabetes Care,2017,40(11):1479-1485.
[13]	刘圆,孟浩宇,杨志健. 钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭治疗中的研究进展[J]. 中国心血管杂志,2019,24(1):86-88.
[14]	陈忆琳. SGLT2抑制剂在糖尿病肾病治疗中的研究进展[D]. 南昌: 南昌大学硕士学位论文, 2017.
[15]	Stratton I M,Adler A I,Neil H A,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35):Prospective observational study[J]. BMJ,2000,321(7258):405-412. doi: 10.1136/bmj.321.7258.405
[16]	MatthaeiS,Bowering K,Rohwedder K,et al. Durability and tolerability of dapagliflozin over 52 weeks as addon to metformin and sulphonylurea in type 2 diabetes[J]. Diabetes Obes Metab,2015,17(11):1075-1084. doi: 10.1111/dom.12543
[17]	Atageldiyeva K,Fujita Y,Yanagimachi T,et al. Sodiumglucose cotransporter 2 inhibitor and a low carbohydrate diet affect gluconeogenesis and glycogen content differently in the kidney and the liver of non-diabetic mice[J]. PLoS One,2016,11(6):e0157672. doi: 10.1371/journal.pone.0157672
[18]	Yang B,Zhao X H,Ma G B. Role of serum β2-microglobulin, glycosylated hemoglobin,and vascular endothelial growth factor levels in diabetic nephropathy[J]. World Journal of Clinical Cases,2022,10(23):8205-8211.
[19]	Kielstein J T,Pontremoli R,Burnier M,et al. Management of hyperuricemia in patients with chronic kidney disease:A focus on renal protection[J]. Current Hypertension Reports,2020,22(12):1-11.
[20]	Bakris G L,Agarwal R,Anker S D,et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med,2020,383(23):2219-2229.
[21]	Wolf G,Ziyadeh F N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy[J]. Nephron Physiol,2007,106(2):26-31. doi: 10.1159/000101797
[22]	Vallon V,Gerasimova M,Rose M A,et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice[J]. Am J Physiol Ren Physiol,2014,306(2):F194-F204. doi: 10.1152/ajprenal.00520.2013

Relative Articles(20)

Relative Articles

[1]	Liyuan YUN, Junfeng WANG, Ning GUO, Ruimei DING, Haipeng LI, Xueping ZHANG. Analysis of the Efficacy and Safety of GM1 Injection Combined with Batroxobin in the Treatment of Sudden Deafness Patients. Journal of Kunming Medical University, 2024, 45(6): 140-144. doi: 10.12259/j.issn.2095-610X.S20240619
[2]	Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411
[3]	Yanfei WANG, Juan MA, Yunqiao YANG. Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure. Journal of Kunming Medical University, 2022, 43(11): 136-140. doi: 10.12259/j.issn.2095-610X.S20221117
[4]	Xiaolin LIU, Xiaocui CHEN, Yang SUN, Minli LI, Yinglei MIAO. Clinical Efficacy and Safety Evaluation of Fecal Bacteria Transplantation by Different Ways on Ulcerative Colitis. Journal of Kunming Medical University, 2022, 43(6): 46-51. doi: 10.12259/j.issn.2095-610X.S20220612
[5]	Guo-qiang XUE, Xin-xin WEI, Na YAO, Wen-hua ZHAO. Metformin Protects Type II Diabetic Kidneys by Regulating PARP-1 Activity. Journal of Kunming Medical University, 2021, 42(6): 29-37. doi: 10.12259/j.issn.2095-610X.S20210632
[6]	Yi ZENG, Yun-juan LIAO, Ying LI, Zhen-kun HE. Efficacy of Dapagliflozin on Early Diabetic Nephropathy and Its Effect on Serum MCP-1 and IL-6. Journal of Kunming Medical University, 2021, 42(12): 41-46. doi: 10.12259/j.issn.2095-610X.S20211218
[7]	Pan Zi Peng . Analysis and Safety Evaluation of the Clinical Efficacy of Laparoscopic Appendectomy for Acute Appendicitis. Journal of Kunming Medical University,
[8]	Luo Yong Li . Clinical Assessment on the Safety of Cardiac Rehabilitation for the Elderly Patients with Chronic Heart Failure. Journal of Kunming Medical University,
[9]	Xiang Xi . The Correlation between Vitamin D Receptor Gene FokI Single Nucleotide Polymorphism and Diabetic Kidney Disease. Journal of Kunming Medical University,
[10]	Chang Song Jie . The Clinical Efficacy and Safety of Decreasing Blood Uric Acid by Benzene Bromine Malone in Treatment of Hyperuricemia with Elderly Hypertension and Diabetes Mellitus. Journal of Kunming Medical University,
[11]	Zeng Hai Ping . . Journal of Kunming Medical University,
[12]	Xiang Xi . . Journal of Kunming Medical University,
[13]	Li Hui Fang . . Journal of Kunming Medical University,
[14]	An Xin Huan . . Journal of Kunming Medical University,
[15]	Wang Xing Ning . . Journal of Kunming Medical University,
[16]	Mao Wen Wen . . Journal of Kunming Medical University,
[17]	Li Wei . . Journal of Kunming Medical University,
[18]	Tang Li Li . . Journal of Kunming Medical University,
[19]	. Protective Effect of α-Thioctic Acid on Early Type 2 Diabetics Nephropathy. Journal of Kunming Medical University,
[20]	Li Mei Rui . . Journal of Kunming Medical University,